TCGA‐cancer survival data were divided into KRAS wild type and KRAS mutation subgroups.[19] Within the KRAS mutant subgroup, lower RNA expression of PTK2 (FAK coding gene) correlates with better survival outcomes, while for KRAS wild type subgroup, there is no difference between the PTK2 low and high expression groups (Figure 1A,B), suggesting that FAK may be an informative biomarker for aberrant KRAS signaling induced cancer development. The gene discussed is KRAS; the disease is cancer.